- Home
- TRNO vs PCVX Comparison
TRNO vs PCVX Comparison
Compare TRNO & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRNO | PCVX |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.1B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRNO | PCVX |
|---|---|---|
| Price | $62.77 | $53.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $65.58 | ★ $105.00 |
| AVG Volume (30 Days) | 597.6K | ★ 991.0K |
| Earning Date | 02-05-2026 | 02-24-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 75.67 | N/A |
| EPS | ★ 3.15 | N/A |
| Revenue | ★ $442,611,000.00 | N/A |
| Revenue This Year | $23.60 | N/A |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | $19.87 | ★ N/A |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $48.18 | $27.66 |
| 52 Week High | $69.20 | $93.77 |
Technical Indicators
Market Signals| Indicator | TRNO | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 70.44 |
| Support Level | $58.77 | $44.85 |
| Resistance Level | $62.73 | $48.93 |
| Average True Range (ATR) | 1.08 | 2.55 |
| MACD | 0.41 | 0.61 |
| Stochastic Oscillator | 92.15 | 97.25 |
Price Performance
Historical ComparisonAbout TRNO Terreno Realty Corporation
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.